ABSTRACT
Metronomic chemotherapy's antiangiogenic potential has been further expanded upon since its introduction in 2000. The fact that chemotherapy has direct effects on cancer cells and also stimulates the immune system demonstrates the fundamental multitargeted character of this treatment strategy. Metronomic chemotherapy has seen a dramatic increase in clinical trials over the past decade, and it is increasingly being used in combination with standard treatments like radiotherapy and maximum tolerated dose (MTD) chemotherapy and with new treatment approaches like immunotherapy, targeted substances, and drug repositioning. Here, we take a look at the recent developments in our knowledge of the elements linked to disease resistance and the intricate mechanisms by which metronomic chemotherapy works. In this review, we will go through the most recent research-based clinical evidence, including both pediatric and adult populations, as well as highlight active clinical trials. Here, we provide our best guesses as to how metronomic chemotherapy may evolve in the years to come, focusing on its possible place in the modern era of personalized treatment.
